Your browser doesn't support javascript.
loading
Emerging connectivity of programmed cell death pathways and pulmonary vascular remodelling during pulmonary hypertension.
Yuan, Meng-Nan; Liu, Ting; Cai, An-Qi; Zhan, Zibo; Cheng, Yi-Li; Wang, Qi-Yue; Xia, Yu-Xuan; Shen, Nong-Er; Huang, Ping; Zou, Xiao-Zhou.
Affiliation
  • Yuan MN; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Liu T; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
  • Cai AQ; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Zhan Z; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
  • Cheng YL; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Wang QY; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
  • Xia YX; School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Shen NE; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Huang P; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
  • Zou XZ; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
J Cell Mol Med ; 28(16): e70003, 2024 Aug.
Article in En | MEDLINE | ID: mdl-39153207
ABSTRACT
Pulmonary hypertension (PH) is a chronic progressive vascular disease characterized by abnormal pulmonary vascular resistance and pulmonary artery pressure. The major structural alteration during PH is pulmonary vascular remodelling, which is mainly caused by the imbalance between proliferation and apoptosis of pulmonary vascular cells. Previously, it was thought that apoptosis was the only type of programmed cell death (PCD). Soon afterward, other types of PCD have been identified, including autophagy, pyroptosis, ferroptosis and necroptosis. In this review, we summarize the role of the above five forms of PCD in mediating pulmonary vascular remodelling, and discuss their guiding significance for PH treatment. The current review could provide a better understanding of the correlation between PCD and pulmonary vascular remodelling, contributing to identify new PCD-associated drug targets for PH.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apoptosis / Vascular Remodeling / Hypertension, Pulmonary Limits: Animals / Humans Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apoptosis / Vascular Remodeling / Hypertension, Pulmonary Limits: Animals / Humans Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom